- Tytuł:
- Retrospective assessment of everolimus treatment in patients suffering from advanced renal cell carcinoma
- Autorzy:
-
Hernik, Paweł
Kruczała, Maksymilian
Ziobro, Marek - Powiązania:
- https://bibliotekanauki.pl/articles/773514.pdf
- Data publikacji:
- 2017
- Wydawca:
- Medical Education
- Tematy:
-
everolimus
renal cell carcinoma
targeted therapy - Opis:
- Objective: Results of second-line everolimus treatment in clear cell renal carcinoma. Material and methods: Clinical data of 32 patients of the Clinic of Systemic and Metastatic Malignancies, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute (Krakow Branch) treated with second-line everolimus between 2011 and 2016 were analysed. Results: Median progression-free survival was 7 months. Stable disease was observed in 24 cases. Adverse events occurred in 59% of all patients, and the majority were mild and moderate (G1 and G2) according to CTCAE. The most frequent adverse events included anaemia, stomatitis, rash and fatigue. Conclusion: Molecularly targeted drugs offer the only effective and available therapy in Poland, which can be administered in patients with advanced renal cell carcinoma. Second-line everolimus is a valuable therapeutic option in the above mentioned group (following progression on first-line TKI therapy), especially when it is necessary to avoid the accumulation of similar adverse events after TKI treatment (different toxicity profiles).
- Źródło:
-
OncoReview; 2017, 7, 2; 88-91
2450-6125 - Pojawia się w:
- OncoReview
- Dostawca treści:
- Biblioteka Nauki
Artykuł